Halozyme Therapeutics, Inc. vs. REGENXBIO Inc.
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| HALO | RGNX | |
|---|---|---|
| Market Cap | $12.33 billion | $531.74 million |
| Revenue (TTM) | $1.66 billion | $174.48 million |
| Net Income (TTM) | $413.60 million | $-196,432,000 |
HALO leads on 3 of 3 size & scale factors.
Valuation
| HALO | RGNX | |
|---|---|---|
| P/E Ratio | 31.87 | — |
| Price / Book | 85.90 | 7.41 |
| Price / Sales | 7.41 | 3.05 |
RGNX leads on 2 of 2 valuation factors.
Profitability
| HALO | RGNX | |
|---|---|---|
| Net Margin | 24.86% | -112.58% |
| Return on Equity | 288.13% | -273.72% |
HALO leads on 2 of 2 profitability factors.
Risk & Sentiment
| HALO | RGNX | |
|---|---|---|
| Short Interest | 9.79% | 1.96% |
RGNX leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, RGNX overview, RGNX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.